Biomadison, Inc.
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
8
Ending by 2030
Mar 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 30, 2026The maintenance fee for Vesicles for characterization of botulinum neurotoxins (US 11,661,442) comes due Nov 30, 2026. Unpaid by Jun 1, 2027, it lapses early.
- 2 fees due Dec 11 to 27, 2026 · next Dec 11
- 1 fee due Apr 15, 2027The maintenance fee for Botulinum Neurotoxins with Modified Light Chain Specifity and Methods for Producing Same (US 10,441,640) comes due Apr 15, 2027. Unpaid by Oct 15, 2027, it lapses early.
- 1 fee due Jun 17, 2027The maintenance fee for Non-FRET cell based assay (US 10,508,135) comes due Jun 17, 2027. Unpaid by Dec 17, 2027, it lapses early.
- 1 fee due Jul 7, 2027The maintenance fee for Compositions and Methods for Improved Neurotoxin Assays (US 10,526,637) comes due Jul 7, 2027. Unpaid by Jan 7, 2028, it lapses early.
- 1 fee due Sep 1, 2027The maintenance fee for Non-FRET botulinum assay (US 9,274,121) comes due Sep 1, 2027. Unpaid by Mar 1, 2028, it lapses early.
- 1 fee due Oct 5, 2027The maintenance fee for Resonance Energy Transfer Assay with Cleavage Sequence and Spacer (US 9,303,284) comes due Oct 5, 2027. Unpaid by Apr 5, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,969,016 | Resonance Energy Transfer Assay with Cleavage Sequence and Spacer In force · High confidence | In force | High confidence | |
| US 9,677,113 | Resonance Energy Transfer Assay with Cleavage Sequence and Spacer In force · High confidence | In force | High confidence | |
| US 9,988,666 | Resonance Energy Transfer Assay with Cleavage Sequence and Spacer In force · High confidence | In force | High confidence | |
| US 10,526,637 | Compositions and Methods for Improved Neurotoxin Assays In force · High confidence | In force | High confidence | |
| US 10,508,135 | Non-FRET cell based assay In force · From the USPTO record | In force | From the USPTO record | |
| US 10,975,125 | Reporting constructs for characterization of Botulinum neurotoxins In force · From the USPTO record | In force | From the USPTO record | |
| US 12,054,516 | Cells for Characterization of Botulinum Neurotoxins In force · Medium confidence | In force | Medium confidence | |
| US 12,344,634 | Peptides for Characterization of Botulinum Neurotoxins In force · Medium confidence | In force | Medium confidence | |
| US 9,453,254 | Resonance energy transfer assay with synaptobrevin substrate moiety In force · From the USPTO record | In force | From the USPTO record | |
| US 11,661,442 | Vesicles for characterization of botulinum neurotoxins In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 34: 2 patents in force now held by others. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending · 1 no status recorded